Medtronic Raises Fiscal 2027 Forecasts Amid Heart Device Demand Surge

Medtronic has revised its fiscal 2027 financial projections, buoyed by a surge in demand for heart devices used in complex cardiovascular procedures. The company announced an increase in its revenue growth forecast as well as the lower end of its profit expectations.

CEO Geoff Martha highlighted that the company's confidence stems from the strong performance across its various business segments and significant contributions from new growth platforms. Medtronic now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous forecast of 6.75% to 7.25%. The lower end of its adjusted per-share profit forecast has also been raised to $5.94, while the upper limit remains at $6.

Strategic Investments and Expanding Technology

In a strategic move to expand its technological offerings, Medtronic announced an $80 million investment in heart-valve repair device maker Pi-Cardia, with an option to acquire the company for $210 million. Additionally, Medtronic invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select international markets. Martha noted that the adoption of soft tissue robotic surgery in emerging markets is currently below 1%, emphasizing the complementary nature of Cornerstone's Sentire device to Medtronic's Hugo system.

Martha stated that Medtronic is prioritizing investments in high-growth sectors within medtech, focusing on areas with large patient pools. The company's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% increase in its pulsed field ablation portfolio, which is used to treat irregular heart rhythms.

Financial Performance and Market Outlook

For the quarter, Medtronic reported an adjusted per-share profit of $1.45 on revenues of $9.76 billion, surpassing analyst expectations of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

Medtronic's Chief Financial Officer Thierry Pieton noted that the company benefited from tariff refunds that nearly offset the duties paid during the quarter. However, these refunds have not been factored into future financial outlooks.

As Medtronic continues to navigate the evolving medical technology landscape, its strategic investments and focus on high-growth segments position it for sustained growth. The company's enhanced forecasts reflect robust market demand and a commitment to expanding its technological capabilities.